Astex – Oncology and CNS Drug Discovery & Development

Committed to the fight against cancer and CNS disorders

Committed to the fight against cancer and CNS disorders

World leading innovative drug discovery & development

Our research and development teams utilize our cutting edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS.

Astex has built a rich product portfolio with multiple drugs in clinical development

Latest from Astex

12 May 2022

Astex announces that the phase 3 ASCERTAIN – acute myeloid leukemia (AML) clinical study of oral hypomethylating agent decitabine and cedazuridine fixed-dose combination (ASTX727 or DEC-C) met the trial’s primary endpoint

In the News

06 April 2022
Astex enters new partnership with the UK Dementia Research Institute to accelerate progress in dementia research

13 January 2021
Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program

Sustaining Innovation

Innovative postdoctoral research fellowships

Career Opportunities

We seek to attract and retain talented individuals who are passionate about improving patient outcomes.

icon_Interactive_White

Interactive Scientific Resources

Explore 3D protein-ligand structures from recent Astex publications.

Download software developed by Astex scientists.